Who Prioritizes Innovation? R&D Spending Compared for Amgen Inc. and Viking Therapeutics, Inc.

Biotech R&D: Amgen vs. Viking's Innovation Strategies

__timestampAmgen Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 2014429700000022223073
Thursday, January 1, 201540700000006966842
Friday, January 1, 201638400000009000499
Sunday, January 1, 2017356200000013741186
Monday, January 1, 2018373700000019040000
Tuesday, January 1, 2019411600000023559000
Wednesday, January 1, 2020420700000031931000
Friday, January 1, 2021481900000044981000
Saturday, January 1, 2022443400000054234000
Sunday, January 1, 2023478400000063806000
Monday, January 1, 20245964000000
Loading chart...

Unleashing insights

Innovation in Biotech: A Tale of Two Companies

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Amgen Inc., a giant in the industry, has consistently invested heavily in R&D, with expenditures peaking at nearly $4.8 billion in 2021. This represents a steady increase of about 35% from 2014. In contrast, Viking Therapeutics, Inc., a smaller player, has shown a remarkable growth trajectory in its R&D spending, increasing by over 180% from 2014 to 2023. Despite its smaller scale, Viking's commitment to innovation is evident, with its R&D expenses reaching approximately $64 million in 2023. This comparison highlights the diverse strategies in the biotech sector, where both established giants and emerging companies prioritize innovation to drive future growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025